STOCK TITAN
  1. Home
  2. Sec-filings
  3. BSX
  4. [Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity

Boston Scientific (NYSE: BSX) grants RSUs and options to EVP

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Boston Scientific executive Vance R. Brown, EVP, GC and Corporate Secretary, reported equity compensation changes tied to restricted stock units and options. On February 12, 2026, 1,442 restricted stock units were exercised into 1,442 shares of common stock, and 488 shares were disposed of to cover tax withholding at $74.12 per share.

Following these transactions, Brown directly held 34,405 shares of common stock. He also received new grants of 7,420 restricted stock units and 17,510 stock options with a $74.12 exercise price, each vesting in four equal annual installments beginning February 12, 2027.

Positive

  • None.

Negative

  • None.
Insider Brown Vance R
Role EVP, GC and Corp. Secretary
Type Security Shares Price Value
Exercise Restricted Stock Units 1,442 $0.00 --
Grant/Award Restricted Stock Units 7,420 $0.00 --
Grant/Award Stock Option (Right to Buy) 17,510 $0.00 --
Exercise Common Stock 1,442 $0.00 --
Tax Withholding Common Stock 488 $74.12 $36K
Holdings After Transaction: Restricted Stock Units — 2,886 shares (Direct); Stock Option (Right to Buy) — 17,510 shares (Direct); Common Stock — 34,893 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brown Vance R
(Last) (First) (Middle)
300 BOSTON SCIENTIFIC WAY
(Street)
MARLBOROUGH MA 01752-1234
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, GC and Corp. Secretary
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/12/2026 M 1,442 A $0.0000(1) 34,893 D
Common Stock 02/12/2026 F 488 D $74.12 34,405 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/12/2026 M 1,442 (2) 02/12/2028(2) Common Stock 1,442 $0.0000 2,886 D
Restricted Stock Units (1) 02/12/2026 A 7,420 (3) 02/12/2030(3) Common Stock 7,420 $0.0000 7,420 D
Stock Option (Right to Buy) $74.12 02/12/2026 A 17,510 (4) 02/12/2036 Common Stock 17,510 $0.0000 17,510 D
Explanation of Responses:
1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
/s/ Susan Thompson, Attorney-in-Fact 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BSX executive Vance Brown report on February 12, 2026?

Vance Brown reported equity compensation activity on February 12, 2026. He exercised 1,442 restricted stock units into common shares, had 488 shares withheld to cover taxes at $74.12 per share, and reported updated direct ownership and new awards of restricted stock units and stock options.

How many Boston Scientific (BSX) shares does Vance Brown own after these Form 4 transactions?

After the reported transactions, Vance Brown directly owns 34,405 BSX common shares. This reflects the 1,442 shares issued from restricted stock unit vesting and the 488-share tax withholding disposition, as shown in the non-derivative securities table for his direct holdings.

What new restricted stock unit awards did BSX grant to Vance Brown in this filing?

Boston Scientific granted Vance Brown 7,420 new restricted stock units. Each unit represents a commitment to issue one share of common stock. These units are scheduled to be delivered in four equal annual installments beginning February 12, 2027, according to the accompanying footnote disclosures.

What stock options were granted to BSX executive Vance Brown in this Form 4?

Vance Brown received 17,510 stock options with a $74.12 exercise price. The options relate to Boston Scientific common stock and vest in four equal annual installments starting February 12, 2027, with an expiration date of February 12, 2036, as detailed in the derivative securities table.

How were restricted stock units converted to Boston Scientific (BSX) common stock in this report?

1,442 restricted stock units were converted into 1,442 BSX common shares. The conversion was reported with a transaction code M, indicating an exercise or conversion of a derivative security at a price of $0.0000 per unit, consistent with equity-based compensation practices.

Why did Vance Brown dispose of 488 Boston Scientific shares in this filing?

The 488-share disposition was for tax withholding purposes. The transaction used code F, which signifies payment of tax liability by delivering securities, at a price of $74.12 per share, rather than an open-market sale for investment purposes.